Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerlynx and Faslodex in HR+/HER2- Metastatic Breast Cancer
NCT04901299Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2023
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
A Phase 2 trial of neratinib in breast cancer, sponsored by Massachusetts General Hospital. Planned start Jul 2023; status: withdrawn.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04901299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04901299.